{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T23:46:31Z","timestamp":1790725591725,"version":"4.1.0"},"reference-count":36,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T00:00:00Z","timestamp":1771891200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background: Hepatocellular carcinoma (HCC) is a major cause of mortality in the United States, but it can be cured with orthotopic liver transplant (OLT) in selected patients. Despite curative intent, post-OLT recurrence can occur in up to 15% of patients. The need for a program of post-OLT surveillance is widely accepted but the specifics of an optimal program have not been established. There is interest in identifying lower-risk cohorts of patients in whom an abbreviated strategy of surveillance may prove adequate, utilizing tools such as the RETREAT score. Unique challenges are posed in the post-transplant population regarding safety and tolerability of systemic therapy for HCC recurrence, suggesting early detection is beneficial. Methods: This was a single-center retrospective analysis of characteristics and outcomes for all patients undergoing transplant at our center between 1 January 2012 and 31 December 2024. Diagnosis of HCC was determined by histological confirmation or Liver Imaging and Reporting Data System (LI-RADS) 5 findings on contrast-enhanced cross-sectional imaging. RETREAT scores were calculated for all patients. Results: During the study period, 923 transplants were performed, of which 329 (35.6%) were for HCC. Post-OLT recurrence occurred in 36 (10.9%) of these. Recurrence was associated with the presence of any viable tumor on explant surgical pathology, the presence of a viable tumor beyond Milan Criteria, the presence of microvascular invasion, a larger diameter of viable tumor on explant, and a higher RETREAT score. Although higher RETREAT scores were associated with post-OLT recurrence, one-third of patients who experienced post-OLT recurrence had RETREAT scores of 0 or 1. RETREAT scores did not correlate with the time interval between transplant and HCC recurrence. Systemic therapy proved challenging, with 10\/25 patients receiving systemic therapy for post-OLT recurrence having to stop or alter regimens due to the severity of adverse effects. Conclusions: The rates of post-transplant recurrence and the experience of patients managed with systemic therapy for post-OLT recurrence in our experience were in line with previously published data. Due to the overall low RETREAT scores, the sensitivity of the RETREAT score in identifying patients at risk for post-OLT recurrence was limited, and the low RETREAT score had very limited incremental negative predictive value for identifying a low-risk population. This suggested that a broad screening strategy for post-OLT recurrence may be better than a personalized strategy in which patients with low RETREAT scores receive abbreviated surveillance.<\/jats:p>","DOI":"10.3390\/cancers18050721","type":"journal-article","created":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T10:14:44Z","timestamp":1771928084000},"page":"721","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Predicting and Managing Hepatocellular Carcinoma Recurrence After Liver Transplant: A Single-Center Experience 2012\u20132024"],"prefix":"10.3390","volume":"18","author":[{"given":"Jesse","family":"Civan","sequence":"first","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Medicine, Thomas Jefferson University, Philadelphia, PA 19107, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madison","family":"Force","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Medicine, Thomas Jefferson University, Philadelphia, PA 19107, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali Raza","family":"Shaikh","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Thomas Jefferson University, Philadelphia, PA 19107, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6255-2087","authenticated-orcid":false,"given":"Adam","family":"Bodzin","sequence":"additional","affiliation":[{"name":"Department of Surgery, Thomas Jefferson University, Philadelphia, PA 19107, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1352-8915","authenticated-orcid":false,"given":"Daniel","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Thomas Jefferson University, Philadelphia, PA 19107, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,2,24]]},"reference":[{"key":"ref_1","first-page":"10","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Lee, Y.T., Wang, J.J., Danpanichkul, P., Kim, H.S., Kuo, A., Ayoub, W.S., Trivedi, H.D., Wang, Y., Vipani, A., and Martin, P. (2025). Recent Trends of Incidence, Mortality, Treatment, and Overall Survival of Hepatocellular Carcinoma in the United States. Clin. Gastroenterol. Hepatol., epub ahead of print.","DOI":"10.1016\/j.cgh.2025.10.012"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2418","DOI":"10.1016\/j.cgh.2022.07.034","article-title":"Recent Decline in the Incidence of Hepatocellular Carcinoma in the United States","volume":"21","author":"Thrift","year":"2023","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1002\/hep.29485","article-title":"Therapies for patients with hepatocellular carcinoma awaiting liver transplantation: A systematic review and meta-analysis","volume":"67","author":"Kulik","year":"2018","journal-title":"Hepatology"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1111\/ajt.15697","article-title":"Liver transplantation for hepatocellular carcinoma: Management after the transplant","volume":"20","author":"Verna","year":"2020","journal-title":"Am. J. Transplant."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"S193","DOI":"10.1016\/j.ajt.2025.01.022","article-title":"OPTN\/SRTR 2023 Annual Data Report: Liver","volume":"25","author":"Kwong","year":"2025","journal-title":"Am. J. Transplant."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1097\/HEP.0000000000000466","article-title":"AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma","volume":"78","author":"Singal","year":"2023","journal-title":"Hepatology"},{"key":"ref_8","unstructured":"European Association for the Study of the Liver (2025). EASL Clinical Practice Guidelines on the management of hepatocellular carcinoma. J. Hepatol., 82, 315\u2013374."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Expert Panel on Gastrointestinal Imaging, Smith, E.N., Bashir, M.R., Fung, A., Cash, B.D., Dixon, M., Hecht, E.M., McGuire, B.M., Pillai, A.A., and Russo, G.K. (2025). ACR Appropriateness Criteria(R) Staging and Follow-Up of Primary Liver Cancer. J. Am. Coll. Radiol., 22, S699\u2013S712.","DOI":"10.1016\/j.jacr.2025.08.032"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1056\/NEJM199603143341104","article-title":"Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis","volume":"334","author":"Mazzaferro","year":"1996","journal-title":"N. Engl. J. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1097\/HEP.0000000000001297","article-title":"A prospective multicenter validation of RETREAT for posttransplantation HCC recurrence prediction","volume":"82","author":"Li","year":"2025","journal-title":"Hepatology"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1016\/j.jhep.2023.08.020","article-title":"AFP-L3 and DCP strongly predict early hepatocellular carcinoma recurrence after liver transplantation","volume":"79","author":"Norman","year":"2023","journal-title":"J. Hepatol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"100249","DOI":"10.1016\/j.aohep.2020.08.067","article-title":"Usefulness of neutrophil-to-lymphocyte ratio (NLR) as a prognostic predictor after treatment of hepatocellular carcinoma.\u201d Review article","volume":"22","author":"Mouchli","year":"2021","journal-title":"Ann. Hepatol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"5081","DOI":"10.3748\/wjg.v24.i45.5081","article-title":"Multidisciplinary approach for post-liver transplant recurrence of hepatocellular carcinoma: A proposed management algorithm","volume":"24","author":"Au","year":"2018","journal-title":"World J. Gastroenterol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"e26682","DOI":"10.1002\/pbc.26682","article-title":"Fatal orthotopic liver transplant organ rejection induced by a checkpoint inhibitor in two patients with refractory, metastatic hepatocellular carcinoma","volume":"64","author":"Friend","year":"2017","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1038\/ajg.2017.387","article-title":"Preserved Liver Transplant After PD-1 Pathway Inhibitor for Hepatocellular Carcinoma","volume":"112","author":"Varkaris","year":"2017","journal-title":"Am. J. Gastroenterol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1002\/hep.29575","article-title":"Pembrolizumab for metastatic hepatocellular carcinoma following live donor liver transplantation: The silver bullet?","volume":"67","author":"Rammohan","year":"2018","journal-title":"Hepatology"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/liv.15419","article-title":"Immune checkpoint inhibitors in malignancies after liver transplantation: A systematic review and pooled analysis","volume":"43","author":"Kayali","year":"2023","journal-title":"Liver Int."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1097\/LVT.0000000000000550","article-title":"Immune checkpoint inhibitors in the posttransplant landscape of HCC: A systematic literature review","volume":"32","author":"Kahramangil","year":"2024","journal-title":"Liver Transplant."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"e1036","DOI":"10.1002\/onco.13638","article-title":"The Role of Immunotherapy in Hepatocellular Carcinoma: A Systematic Review and Pooled Analysis of 2,402 Patients","volume":"26","author":"Ziogas","year":"2021","journal-title":"Oncologist"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Ma, D., Wei, P., Cheng, Q., Hao, J., Li, Z., Chen, Z., Shi, W., Yuan, Z., Lo, C., and Luo, Y. (2025). Immune checkpoint inhibitors use in liver transplantation for hepatocellular carcinoma: A global cohort study. BMC Med., 23.","DOI":"10.1186\/s12916-025-04352-z"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Jiang, J., Huang, H., Chen, R., Lin, Y., and Ling, Q. (2023). Immunotherapy for hepatocellular carcinoma recurrence after liver transplantation, can we harness the power of immune checkpoint inhibitors?. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1092401"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"295","DOI":"10.2214\/AJR.20.24272","article-title":"LI-RADS: Past, Present, and Future, From the AJR Special Series on Radiology Reporting and Data Systems","volume":"216","author":"Marks","year":"2021","journal-title":"AJR Am. J. Roentgenol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_25","first-page":"EVIDoa2100070","article-title":"Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma","volume":"1","author":"Lau","year":"2022","journal-title":"NEJM Evid."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1016\/S0140-6736(25)00403-9","article-title":"Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): An open-label, randomised, phase 3 trial","volume":"405","author":"Yau","year":"2025","journal-title":"Lancet"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"Llovet","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","article-title":"Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: A randomised phase 3 non-inferiority trial","volume":"391","author":"Kudo","year":"2018","journal-title":"Lancet"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Lo Prinzi, F., Rossari, F., De Rosa, A., Vivaldi, C., Kudo, M., Shimose, S., Suda, G., Camera, S., Foti, S., and Rizzato, M.D. (2025). Efficacy and Safety of Lenvatinib Versus Sorafenib in Recurrent HCC After Liver Transplant: A Multi-Center Real-World Study. Hepatol. Res., early view.","DOI":"10.1111\/hepr.70076"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1056\/NEJMoa1717002","article-title":"Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma","volume":"379","author":"Meyer","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S0140-6736(16)32453-9","article-title":"Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): A randomised, double-blind, placebo-controlled, phase 3 trial","volume":"389","author":"Bruix","year":"2017","journal-title":"Lancet"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/S1470-2045(18)30937-9","article-title":"Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased alpha-fetoprotein concentrations (REACH-2): A randomised, double-blind, placebo-controlled, phase 3 trial","volume":"20","author":"Zhu","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1200\/JCO.23.01498","article-title":"Cemiplimab for Kidney Transplant Recipients With Advanced Cutaneous Squamous Cell Carcinoma","volume":"42","author":"Hanna","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1001\/jamaoncol.2025.2374","article-title":"Outcomes of Solid Organ Transplant Recipients With Advanced Cancers Receiving Immune Checkpoint Inhibitors: A Systematic Review and Individual Participant Data Meta-Analysis","volume":"11","author":"Saleem","year":"2025","journal-title":"JAMA Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.jhep.2024.09.003","article-title":"Intention-to-treat outcomes of patients with hepatocellular carcinoma receiving immunotherapy before liver transplant: The multicenter VITALITY study","volume":"82","author":"Tabrizian","year":"2025","journal-title":"J. Hepatol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/j.transproceed.2023.03.064","article-title":"Optimizing the Safe Washout Period for Liver Transplantation Following Immune Checkpoint Inhibitors with Atezolizumab, Nivolumab, or Pembrolizumab","volume":"55","author":"Kuo","year":"2023","journal-title":"Transplant. Proc."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/5\/721\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T10:33:53Z","timestamp":1771929233000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/5\/721"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,24]]},"references-count":36,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,3]]}},"alternative-id":["cancers18050721"],"URL":"https:\/\/doi.org\/10.3390\/cancers18050721","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,24]]}}}